Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02162888
Title A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eagle Pharmaceuticals, Inc.
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Bendamustine

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Oncology Institute of Hope and Innovation Long Beach California United States Details
Cancer Center of Kansas Wichita Kansas United States Details
Regional Cancer Care Associates Cherry Hill New Jersey United States Details
Penn State University Hershey Medical Center Hershey Pennsylvania United States Details
Greenville Hospital System University Medical Center Greenville South Carolina United States Details
Texas Oncology Fort Worth Texas United States Details
Scott & White Healthcare Temple Texas United States Details
Virginia Oncology Associates Norfolk Virginia United States Details
Evergreen Hematology & Oncology Spokane Washington United States Details
Yakima Valley Memorial Hospital/North Star Lodge Yakima Washington United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field